FDA expands approval of Brentuximab Vedotin for first-line treatment of Stage III or IV classical Hodgkin lymphoma in combination with chemotherapy

March 20, 2018 – The U.S. Food and Drug Administration today approved brentuximab vedotin to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy. “Today’s approval represents an improvement in the initial treatment regimens of advanced Hodgkin lymphoma that were introduced into clinical practice more than 40 years ago,” said Richard Pazdur, M.D., director of the FDA’s Oncology … (leggi tutto)